Kappa-Opioid Receptor Stimulation Quickens Pathogenesis of Compulsive Checking in the Quinpirole Sensitization Model of Obsessive-Compulsive Disorder (OCD)

Behavioral Neuroscience

Volumn 121, Issue 5, 2007, Pages 976-991

  Perreault, Melissa L ^a   Seeman, Philip ^b   Szechtman, Henry ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

animal model; components of sensitization; development of obsessive compulsive disorder (OCD); dopamine D2High affinity binding; kappa opioid dopamine receptors co activation

Indexed keywords

8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; DOMPERIDONE; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; KAPPA OPIATE RECEPTOR; KAPPA OPIATE RECEPTOR AGONIST; N METHYL N [7 (1 PYRROLIDINYL) 1 OXASPIRO[4.5]DEC 8 YL]BENZENEACETAMIDE; QUINPIROLE; RACLOPRIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING COMPETITION; CONTROLLED STUDY; CORPUS STRIATUM; DRUG POTENTIATION; DRUG RECEPTOR BINDING; LOCOMOTION; MALE; NONHUMAN; NUCLEUS ACCUMBENS; OBSESSIVE COMPULSIVE DISORDER; RAT; RECEPTOR AFFINITY; SENSITIZATION;

(R)-2,3,4,5-TETRAHYDRO-8-CHLORO-3-METHYL-5-PHENYL-1H-3-BENZAZEPIN-7-OL; ALGORITHMS; ANIMALS; BENZENEACETAMIDES; DOMPERIDONE; DOPAMINE AGONISTS; DOPAMINE ANTAGONISTS; HYPERKINESIS; KINETICS; LIGANDS; MALE; MOTOR ACTIVITY; OBSESSIVE-COMPULSIVE DISORDER; PYRROLIDINES; QUINPIROLE; RACLOPRIDE; RATS; RATS, LONG-EVANS; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3; RECEPTORS, OPIOID, KAPPA; STEREOTYPED BEHAVIOR;

EID: 35748954389     PISSN: 07357044     EISSN: None     Source Type: Journal    
DOI: 10.1037/0735-7044.121.5.976     Document Type: Article

References (67)

1. 2 receptor function by the selective kappa-opioid receptor agonist U69593. Synapse 39 (2001) 343-350
2. Ben Pazi A., Szechtman H., and Eilam D. The morphogenesis of motor rituals in rats treated chronically with the dopamine agonist quinpirole. Behavioral Neuroscience 115 (2001) 1301-1317
3. 1 receptors of the ventral tegmental area in the behavioral sensitization induced by intra-ventral tegmental area injections of D-amphetamine. Journal of Pharmacology and Experimental Therapeutics 277 (1996) 1177-1187
4. Boyer P., and Lienard P. Why ritualized behavior? Precaution systems and action parsing in developmental, pathological and cultural rituals. Behavioral Brain Sciences 29 (2006) 595-613
5. Brown R.W., Thompson K.D., Thompson K.N., Ward J.J., Thacker S.K., Williams M.T., and Kostrzewa R.M. Adulthood nicotine treatment alleviates behavioural impairments in rats neonatally treated with quinpirole: Possible roles of acetylcholine function and neurotrophic factor expression. European Journal of Neuroscience 19 (2004) 1634-1642
6. 2 agonist-enhancement of locomotor activity in 6-hydroxydopamine-lesioned rats. Neurotoxicity Research 5 (2003) 329-338
7. Carlezon Jr. W.A., and Nestler E.J. Elevated levels of GluR1 in the midbrain: A trigger for sensitization to drugs of abuse?. Trends in Neurosciences 25 (2002) 610-615
8. Chavkin C., Sud S., Jin W., Stewart J., Zjawiony J.K., Siebert D.J., et al. Salvinorin A, an active component of the hallucinogenic sage salvia divinorum is a highly efficacious kappa-opioid receptor agonist: Structural and functional considerations. Journal of Pharmacology and Experimental Therapeutics 308 (2004) 1197-1203
9. Curran E.J., and Watson Jr. S.J. Dopamine receptor mRNA expression patterns by opioid peptide cells in the nucleus accumbens of the rat: A double in situ hybridization study. Journal of Comparative Neurology 361 (1995) 57-76
10. Dvorkin A., Culver K.E., and Szechtman H. Differential effects of clorgyline on sensitization to quinpirole in rats tested in small and large environments. Psychopharmacology 186 (2006) 534-543
11. Dvorkin A., Perreault M.L., and Szechtman H. Development and temporal organization of compulsive checking induced by repeated injections of the dopamine agonist quinpirole in an animal model of obsessive-compulsive disorder. Behavioural Brain Research 169 (2006) 303-311
12. Eilam D., and Golani I. Home base behavior of rats (Rattus norvegicus) exploring a novel environment. Behavioural Brain Research 34 (1989) 199-211
13. Eilam D., and Szechtman H. Psychostimulant-induced behavior as an animal model of obsessive-compulsive disorder: An ethological approach to the form of compulsive rituals. CNS Spectrums 10 (2005) 191-202
14. Eilam D., Zor R., Szechtman H., and Hermesh H. Rituals, stereotypy and compulsive behavior in animals and humans. Neuroscience and Biobehavioral Reviews 30 (2006) 456-471
15. Einat H., Einat D., Allan M., Talangbayan H., Tsafnat T., and Szechtman H. Associational and nonassociational mechanisms in locomotor sensitization to the dopamine agonist quinpirole. Psychopharmacology 127 (1996) 95-101
16. Feygin D.L., Swain J.E., and Leckman J.F. The normalcy of neurosis: Evolutionary origins of obsessive-compulsive disorder and related behaviors. Progress in Neuro-Psychopharmacology and Biological Psychiatry 30 (2006) 854-864
17. Fontenelle L.F., Nascimento A.L., Mendlowicz M.V., Shavitt R.G., and Versiani M. An update on the pharmacological treatment of obsessive-compulsive disorder. Expert Opinion on Pharmacotherapy 8 (2007) 563-583
18. 2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science 250 (1990, December 7) 1429-1432
19. Gonzalez D., Riba J., Bouso J.C., Gomez-Jarabo G., and Barbanoj M.J. Pattern of use and subjective effects of Salvia divinorum among recreational users. Drug and Alcohol Dependence 85 (2006) 157-162
20. Joel D. Current animal models of obsessive compulsive disorder: A critical review. Progress in Neuro-Psychopharmacology and Biological Psychiatry 30 (2006) 374-388
21. Kelley A.E., Baldo B.A., and Pratt W.E. A proposed hypothalamic-thalamic-striatal axis for the integration of energy balance, arousal, and food reward. Journal of Comparative Neurology 493 (2005) 72-85
22. Korff S., and Harvey B.H. Animal models of obsessive-compulsive disorder: Rationale to understanding psychobiology and pharmacology. Psychiatric Clinics of North America 29 (2006) 371-390
23. Lefever D.W. Measuring geographic concentration by means of the standard deviation ellipse. American Journal of Sociology 32 (1926) 88-94
24. 2 mRNAs in distinct neuronal populations of the dorsal and ventral striatum. Journal of Comparative Neurology 355 (1995) 418-426
25. 1 dopamine receptor gene. Proceedings of the National Academy of Sciences, USA, 88, 4205-4209.
26. Levine N. CrimeStat III: A spatial statistics program for the analysis of crime incident locations (Version 3.0) (2004). http://www.nedlevine.com/nedlevine17.htm Retrieved July 24, 2007, from http://www.nedlevine.com/nedlevine17.htm
27. Lundberg S., Carlsson A., Norfeldt P., and Carlsson M.L. Nicotine treatment of obsessive-compulsive disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry 28 (2004) 1195-1199
28. Man J., Hudson A.L., Ashton D., and Nutt D.J. Animal models for obsessive-compulsive disorder. Current Neuropharmacology 2 (2004) 169-181
29. Martin, S. A. (2001). The effects of the pharmacotherapeutic agent clomipramine on compulsive checking in rats. Unpublished master's thesis, McMaster University, Hamilton, Ontario, Canada.
30. Mattingly B.A., Rowlett J.K., and Lovell G. Effects of daily SKF 38393, quinpirole, and SCH 23390 treatments on locomotor activity and subsequent sensitivity to apomorphine. Psychopharmacology 110 (1993) 320-326
31. McDougle C.J., Barr L.C., Goodman W.K., and Price L.H. Possible role of neuropeptides in obsessive compulsive disorder. Psychoneuroendocrinology 24 (1999) 1-24
32. Merg F., Filliol D., Usynin I., Bazov I., Bark N., Hurd Y.L., et al. Big dynorphin as a putative endogenous ligand for the kappa-opioid receptor. Journal of Neurochemistry 97 (2006) 292-301
33. Noldus L.P., Spink A.J., and Tegelenbosch R.A. EthoVision: A versatile video tracking system for automation of behavioral experiments. Behavior Research Methods & Instrumentation 33 (2001) 398-414
34. 3 agonist quinpirole: Pre- and postsynaptic mechanisms. Neuropsychopharmacology 31 (2006) 1967-1981
35. 2 receptor and prodynorphin mRNA expression in rats. Psychopharmacology (Berl) (2007). http://dx.doi.org/10.1007/s00213-007-0855-3 Advance online publication. Retrieved July 10, 2007, from http://dx.doi.org/10.1007/s00213-007-0855-3
36. Petrov E.S., Nizhnikov M.E., Varlinskaya E.I., and Spear N.E. Dynorphin A (1-13) and responsiveness of the newborn rat to a surrogate nipple: Immediate behavioral consequences and reinforcement effects in conditioning. Behavioural Brain Research 170 (2006) 1-14
37. Petrov E.S., Varlinskaya E.I., and Smotherman W.P. The first suckling episode in the rat: The role of endogenous activity at mu and kappa opioid receptors. Developmental Psychobiology 37 (2000) 129-143
38. Roth, B. L., Baner, K., Westkaemper, R., Siebert, D., Rice, K. C., Steinberg, S., et al. (2002). Salvinorin A: A potent naturally occurring nonnitrogenous kappa opioid selective agonist. Proceedings of the National Academy of Sciences, USA, 99, 11934-11939.
39. Salin-Pascual R.J., and Basanez-Villa E. Changes in compulsion and anxiety symptoms with nicotine transdermal patches in non-smoking obsessive-compulsive disorder patients. Revista de Investigacion Clinica 55 (2003) 650-654
40. 3(high) receptors. Synapse 58 (2005) 122-128
41. 2(high) dopamine receptors. Synapse 60 (2006) 319-346
42. 2 receptor, but not [3H]raclopride or [3H]spiperone in isotonic medium: Implications for human positron emission tomography. Synapse 49 (2003) 209-215
43. 2(high) receptors, reversed by general anesthesia: Relation to relapse?. Synapse 52 (2004) 77-83
44. 2(high) receptors occupied by endogenous dopamine, even in the absence of acute challenges. Synapse 46 (2002) 235-239
45. 2(high) states, implying many paths to psychosis. Proceedings of the National Academy of Sciences, USA, 102, 3513-3518.
46. 3 receptors in human putamen, caudate nucleus, and globus pallidus. Synapse 60 (2006) 205-211
47. Sheffler D.J., and Roth B.L. Salvinorin A: The "magic mint" hallucinogen finds a molecular target in the kappa opioid receptor. Trends in Pharmacological Sciences 24 (2003) 107-109
48. Spink A.J., Tegelenbosch R.A., Buma M.O., and Noldus L.P. The EthoVision video tracking system-a tool for behavioral phenotyping of transgenic mice. Physiology & Behavior 73 (2001) 731-744
49. Szechtman H., Culver K., and Eilam D. Role of dopamine systems in obsessive-compulsive disorder (OCD): Implications from a novel psychostimulant-induced animal model. Polish Journal of Pharmacology 51 (1999) 55-61
50. Szechtman H., Dai H., Mustafa S., Einat H., and Sullivan R.M. Effects of dose and interdose interval on locomotor sensitization to the dopamine agonist quinpirole. Pharmacology, Biochemistry and Behavior 48 (1994) 921-928
51. Szechtman H., Eckert M.J., Tse W.S., Boersma J.T., Bonura C.A., McClelland J.Z., et al. Compulsive checking behavior of quinpirole-sensitized rats as an animal model of obsessive-compulsive disorder (OCD): Form and control. BMC Neuroscience 2 (2001) 4
52. Szechtman H., and Eilam D. Psychiatric models. In: Whishaw I.Q., and Kolb B. (Eds). The behavior of the laboratory rat: A handbook with tests (2005), Oxford University Press, New York 462-474
53. Szechtman H., Sulis W., and Eilam D. Quinpirole induces compulsive checking behavior in rats: A potential animal model of obsessive-compulsive disorder (OCD). Behavioral Neuroscience 112 (1998) 1475-1485
54. Szechtman H., Talangbayan H., Canaran G., Dai H., and Eilam D. Dynamics of behavioral sensitization induced by the dopamine agonist quinpirole and a proposed central energy control mechanism. Psychopharmacology (Berlin) 115 (1994) 95-104
55. Szechtman H., Talangbayan H., and Eilam D. Environmental and behavioral components of sensitization induced by the dopamine agonist quinpirole. Behavioural Pharmacology 4 (1993) 405-410
56. Szechtman H., and Woody E.Z. Obsessive-compulsive disorder as a disturbance of security motivation. Psychological Review 111 (2004) 111-127
57. Szechtman H., and Woody E.Z. Obsessive-compulsive disorder as a disturbance of security motivation: Constraints on comorbidity. Neurotoxicity Research 10 (2006) 103-112
58. Szumlinski K.K., Allan M., Talangbayan H., Tracey A., and Szechtman H. Locomotor sensitization to quinpirole: Environment-modulated increase in efficacy and context-dependent increase in potency. Psychopharmacology 134 (1997) 193-200
59. Tizabi Y., Louis V.A., Taylor C.T., Waxman D., Culver K.E., and Szechtman H. Effect of nicotine on quinpirole-induced checking behavior in rats: Implications for obsessive-compulsive disorder. Biological Psychiatry 51 (2002) 164-171
60. Ulloa R.E., Nicolini H., and Fernandez-Guasti A. Age differences in an animal model of obsessive-compulsive disorder: Participation of dopamine: Dopamine in an animal model of OCD. Pharmacology, Biochemistry and Behavior 78 (2004) 661-666
61. 1 dopamine receptor activation is necessary for the induction of sensitization by amphetamine in the ventral tegmental area. Journal of Neuroscience 16 (1996) 2411-2420
62. Westenberg H.G., Fineberg N.A., and Denys D. Neurobiology of obsessive-compulsive disorder: Serotonin and beyond. CNS Spectrums 12 (2007) 14-27
63. Whishaw I.Q., Gharbawie O.A., Clark B.J., and Lehmann H. The exploratory behavior of rats in an open environment optimizes security. Behavioural Brain Research 171 (2006) 230-239
64. Willner P., Papp M., Cheeta S., and Muscat R. Environmental influences on behavioural sensitization to the dopamine agonist quinpirole. Behavioural Pharmacology 3 (1992) 43-50
65. Woody E.Z., and Szechtman H. Motivation, time course, and heterogeneity in obsessive-compulsive disorder: Response to Taylor, McKay, and Abramowitz (2005). Psychological Review 112 (2005) 658-661
66. Zadicario P., Ronen S., and Eilam D. Modulation of quinpirole-induced compulsive-like behavior in rats by environmental changes: Implications for OCD rituals and for exploration and navigation. BMC Neuroscience 8 (2007) 23
67. Zor, R., Hermesh, H., Szechtman, H., & Eilam, D. (in press). OCD rituals: Turning a hierarchical order into chaos by repetition and addition of acts. World Psychiatry Journal